Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 201-762-9 | CAS number: 87-66-1
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Data are available for the oral and dermal route.
Only reliability 4 type of information are available for the oral route.
In the dermal route repeated dose toxicity studies, significant adverse effects were seen only at local level (skin, at the Site of Administration).
Key value for chemical safety assessment
- Toxic effect type:
- dose-dependent
Repeated dose toxicity: via oral route - systemic effects
Link to relevant study records
- Endpoint:
- short-term repeated dose toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Reliability:
- 4 (not assignable)
- Rationale for reliability incl. deficiencies:
- abstract
- Qualifier:
- no guideline available
- Principles of method if other than guideline:
- - Principle of test:
a repeated dose test was performed to rabbit
- Short description of test conditions: no data
- Parameters analysed / observed: mortality and effects related to administration of the substance - GLP compliance:
- not specified
- Specific details on test material used for the study:
- no data
- Species:
- rabbit
- Strain:
- not specified
- Details on species / strain selection:
- no data
- Sex:
- not specified
- Details on test animals or test system and environmental conditions:
- no data
- Route of administration:
- oral: gavage
- Details on route of administration:
- no data
- Vehicle:
- not specified
- Details on oral exposure:
- no data
- Analytical verification of doses or concentrations:
- not specified
- Duration of treatment / exposure:
- 10-day exposure
- Frequency of treatment:
- no data
- Dose / conc.:
- 500 mg/kg bw/day (nominal)
- Dose / conc.:
- 1 000 mg/kg bw/day (nominal)
- No. of animals per sex per dose:
- total of animals tested: 6
Sex: n.p. - Control animals:
- not specified
- Details on study design:
- observation period n.p.
- Positive control:
- no data
- Key result
- Dose descriptor:
- other: repeated-dose LD50
- Effect level:
- 700 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- not specified
- Basis for effect level:
- mortality
- Conclusions:
- In rabbits, a multiple oral dose (LD50) of pyrogallol is 0.7 g/kg per day when administered daily for ten days.
Reference
A repeated-dose LD50 of 700 mg/kg/day was determined. The following symptoms were observed in some treated rabbits: congestion of the lung; congestion of the liver, with prominent lobules (alternate light and congested areas were observed); congestion and swelling of the kidneys; congestion and enlargement of the spleen; and gastritis, usually with hemorrhages and/or ulcers. A smooth white exudate was induced on the gastric mucosa and there was a varying degree of enteritis in the duodenum and cecum. The doses which caused these effects and the number of animals affected were n.p.
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
Repeated dose toxicity: inhalation - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: inhalation - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - systemic effects
Link to relevant study records
- Endpoint:
- sub-chronic toxicity: dermal
- Type of information:
- experimental study
- Adequacy of study:
- weight of evidence
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- test procedure in accordance with generally accepted scientific standards and described in sufficient detail
- Qualifier:
- no guideline available
- Principles of method if other than guideline:
- - Principle of test:
Based on the subchronic studies, the doses for the 2-year studies in rats and mice were 5, 20 and 75 mg/kg of pyrogallol. The study were conducted in both sexes of F344/N rats mice.
- Short description of test conditions: Groups of 50 male and 50 female rats and mice received dermal applications of pyrogallol in 95% ethanol at doses of 5, 20, or 75 mg/kg, or ethanol vehicle control alone, 5 days per week for up to 104 (rats) or 105 (mice) weeks. Body weights were recorded weekly for 13 weeks and monthly thereafter.
- Parameters analysed / observed: The incidences of microscopic non-neoplastic lesions at the site of application were observed. - GLP compliance:
- yes
- Remarks:
- These studies were conducted in compliance with FDA Good Laboratory Practice for nonclinical laboratory studies (21 CFR 58).
- Limit test:
- no
- Specific details on test material used for the study:
- SOURCE OF TEST MATERIAL
- Source and lot/batch No.of test material: Pyrogallol was obtained from Aceto Corporation (Lake Success, NY; lot number 010326).
- Expiration date of the lot/batch: not specified
- Purity test date: Purity was determined by high-performance liquid chromatography with ultraviolet detection to be greater than 99%.
STABILITY AND STORAGE CONDITIONS OF TEST MATERIAL
- Storage condition of test material: not specified
- Stability under test conditions: not specified
- Solubility and stability of the test substance in the solvent/vehicle: not specified
- Reactivity of the test substance with the solvent/vehicle of the cell culture medium: not specified
TREATMENT OF TEST MATERIAL PRIOR TO TESTING
- Treatment of test material prior to testing: not specified
- Preliminary purification step (if any): not specified
- Final dilution of a dissolved solid, stock liquid or gel: not specified
- Final preparation of a solid: not specified
OTHER SPECIFICS: Dose formulations were prepared by mixing pyrogallol and95% ethanol to give the required concentrations. Dose formulations were analyzed three times during the subchronic study and every three months during the chronic study and were within 10% of target pyrogallol concentrations. - Species:
- rat
- Strain:
- Fischer 344
- Remarks:
- F344/N
- Details on species / strain selection:
- not specified
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: obtained from Taconic Farms, Inc. (Germantown, NY)
- Females (if applicable) nulliparous and non-pregnant: [yes/no] not specified
- Age at study initiation: rats were 6–8 weeks old
- Weight at study initiation: not specified
- Fasting period before study: not specified
- Housing: housed individually
- Diet (e.g. ad libitum): Irradiated NTP-2000 wafer feed (Zeigler Brothers, Inc., Gardners, PA) was available ad libitum.
- Water (e.g. ad libitum): tap water (Columbus, OH, municipal supply) was available ad libitum.
- Acclimation period: quarantined for 11 days
DETAILS OF FOOD AND WATER QUALITY: see above
ENVIRONMENTAL CONDITIONS
- Temperature (°C): not specified
- Humidity (%): not specified
- Air changes (per hr): not specified
- Photoperiod (hrs dark / hrs light): not specified
IN-LIFE DATES: From: To: not specified
Animal care and use were in accordance with the Laboratory Animal Welfare Act of 1966 (P.L. 89–544) as amended and the Public Health Service Policy on Humane Care and Use of Animals. Animals were treated humanely and with regard for alleviation of pain and distress. All animals were housed in facilities accredited by the Association for Assessment and Accreditation of Laboratory Animal Care and all procedures were approved by Battelle's Institutional Animal Care and Use Committee. - Type of coverage:
- other: to naïve skin
- Vehicle:
- ethanol
- Details on exposure:
- TEST SITE
- Area of exposure: Pyrogallol was administered over the application site with a Corning Lambda (Corning, Inc., Corning, NY) single channel pipetter with a disposable polyethylene tip
- % coverage: not specified
- Type of wrap if used:
- Time intervals for shavings or clipplings: An area slightly larger than the interscapular application site was clipped 24 hours before the first dose and weekly thereafter.
REMOVAL OF TEST SUBSTANCE
- Washing (if done): not specified
- Time after start of exposure: not specified
TEST MATERIAL
- Amount(s) applied (volume or weight with unit): Dosing volumes were 0.5 mL/kg body weight
- Concentration (if solution):
- Constant volume or concentration used: yes
- For solids, paste formed: not applicable
VEHICLE
- Justification for use and choice of vehicle (if other than water): not specified
- Amount(s) applied (volume or weight with unit): not specified
- Concentration (if solution): 95%
- Lot/batch no. (if required): not specified
- Purity: not specified
USE OF RESTRAINERS FOR PREVENTING INGESTION: not specified - Analytical verification of doses or concentrations:
- not specified
- Details on analytical verification of doses or concentrations:
- not applicable
- Duration of treatment / exposure:
- two -year study
- Frequency of treatment:
- 5 days per week for 104 weeks
- Dose / conc.:
- 5 mg/kg bw/day
- Remarks:
- pyrogallol in 95% ethanol
- Dose / conc.:
- 20 mg/kg bw/day
- Remarks:
- pyrogallol in 95% ethanol
- Dose / conc.:
- 75 mg/kg bw/day
- Remarks:
- pyrogallol in 95% ethanol
- No. of animals per sex per dose:
- Groups of 50 male and 50 female rats
- Control animals:
- yes, concurrent vehicle
- Positive control:
- no
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: no
- Time schedule: not applicable
- Cage side observations checked in table [No.?] were included. not applicable
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: clinical signs were recorded weekly
DERMAL IRRITATION (if dermal study): no
- Time schedule for examinations: not applicable
BODY WEIGHT: Yes
- Time schedule for examinations: recorded weekly.
FOOD CONSUMPTION: no
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: not applicable
FOOD EFFICIENCY: no
- Body weight gain in kg/food consumption in kg per unit time X 100 calculated as time-weighted averages from the consumption and body weight gain data: not applicable
WATER CONSUMPTION: no
- Time schedule for examinations: not applicable
OPHTHALMOSCOPIC EXAMINATION: no
- Time schedule for examinations: not applicable
- Dose groups that were examined: not applicable
HAEMATOLOGY: no
- Time schedule for collection of blood: not applicable
- Anaesthetic used for blood collection: not applicable
- Animals fasted: not applicable
- How many animals: not applicable
- Parameters checked in table [No.?] were examined. not applicable
CLINICAL CHEMISTRY: no
- Time schedule for collection of blood: not applicable
- Animals fasted: not applicable
- How many animals: not applicable
- Parameters checked in table [No.?] were examined. not applicable
URINALYSIS: no
- Time schedule for collection of urine: not applicable
- Metabolism cages used for collection of urine: not applicable
- Animals fasted: not applicable
- Parameters checked in table [No.?] were examined. not applicable
NEUROBEHAVIOURAL EXAMINATION: No
- Time schedule for examinations: not applicable
- Dose groups that were examined: not applicable
- Battery of functions tested: sensory activity / grip strength / motor activity / other: not applicable
OTHER: Weights of major organs were recorded at necropsy, including heart, liver, kidney, lung, testis, uterus, thymus and thyroid gland.
Animals were observed twice daily and clinical findings were recorded monthly beginning at week 5. - Sacrifice and pathology:
- GROSS PATHOLOGY: Not specified
HISTOPATHOLOGY: Yes - Other examinations:
- no other examinations were performed.
- Statistics:
- To determine statistical differences between incidences, Fisher exact test and poly-3 test were used where applicable. Organ and body weight data were analyzed with the parametric multiple comparison procedures of Dunnett and Williams. Analysis of effects on survival used Cox's [25] method for testing two groups for equality and Tarone's life table test to identify dose-related trends.
- Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- Irritation and/or ulceration of the skin at the site of application were the only chemical-related clinical findings and occurred predominantly in the 20 and 75 mg/kg male and female groups.
- Dermal irritation:
- effects observed, treatment-related
- Description (incidence and severity):
- Lesions at the SOA were morphologically similar to those observed in the 3-month study. The incidences of hyperplasia and hyperkeratosis were significantly greater than those in the vehicle control groups in most dosed groups; incidences of inflammation were significantly increased in several groups treated with 20 or 75 mg/kg. In addition to lesions already seen in the 3-months study, sebaceous gland hyperplasia was significantly increased.
- Mortality:
- mortality observed, treatment-related
- Description (incidence):
- Survival of 75 mg/kg female mice was significantly decreased, as 23 female mice were euthanized before study end due to the presence of ulcers at the SOA.
- Body weight and weight changes:
- no effects observed
- Description (incidence and severity):
- Mean body weights of dosed groups of male and female rats and male mice were similar to that of the vehicle control groups. I
- Food consumption and compound intake (if feeding study):
- not examined
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Description (incidence and severity):
- There were no significant changes in the absolute or relative organ weights at necropsy.
- Gross pathological findings:
- not examined
- Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- Squamous papilloma occurs as an exophytic growth composed of an inner connective tissue core with branching fronds covered by an outer layer of hyperplastic squamous epithelium in male rat exposed to 75 mg/kg Pyrogallol for 2 years.
- Histopathological findings: neoplastic:
- not examined
- Other effects:
- not examined
- Dose descriptor:
- LOAEL
- Effect level:
- 5 mg/kg bw/day
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- body weight and weight gain
- clinical signs
- dermal irritation
- histopathology: non-neoplastic
- mortality
- Dose descriptor:
- NOAEL
- Remarks on result:
- not determinable
- Remarks:
- the adverse toxic effect was observed at the first lowest dose
- Critical effects observed:
- yes
- Lowest effective dose / conc.:
- 5 mg/kg bw/day
- System:
- other: Squamous hyperplasia, Hyperkeratosis, Chronic active inflammation, Ulcer
- Organ:
- skin
- Treatment related:
- yes
- Dose response relationship:
- not specified
- Relevant for humans:
- not specified
- Conclusions:
- Skin at the SOA was the primary site of toxicity for pyrogallol for this 3-months study. In conclusion, dermal administration of pyrogallol caused high incidences of nonneoplastic lesions of the skin at the SOA in male and female rats at doses as low as 5 mg/kg/ day. These studies provide the first comprehensive assessment of pyrogallol toxicity in mammals and can be used to assess possible risks to humans from dermal pyrogallol exposure
- Executive summary:
Pyrogallol (CAS No. 87-66-1), a benzenetriol used historically as a hair dye and currently in a number of industrial applications, was nominated to the National Toxicology Program (NTP) for testing based on lack of toxicity and carcinogenicity data. Three-month and two-year toxicity studies to determine the toxicity and carcinogenicity of pyrogallol when applied to naïve skin (i.e. dermal administration) were conducted in both sexes of F344/N rats and B6C3F1/N mice. In the three-month studies, adult rodents were administered pyrogallol in 95% ethanol 5 days per week for 3 months at doses of up to 150 mg /kg body weight (rats) or 600 mg/kg (mice). Based on the subchronic studies, the doses for the 2-year studies in rats and mice were 5, 20 and 75 mg/kg of pyrogallol. All mice and most rats survived until the end of the three-month study and body weights were comparable to controls. During the 2-year study, survival of dosed rats and male
mice was comparable to controls; however survival of 75 mg/kg female mice was significantly decreased compared to controls. The incidences of microscopic non-neoplastic lesions at the site of application were significantly higher in all dosed groups of rats and mice and in both the 3 months and 2-year studies. In the 2-year study, hyperplasia, hyperkeratosis and inflammation tended to be more severe in mice than in rats, and in the mice they tended to be more severe in females than in males. The incidence of squamous cell carcinoma at the site of application (SOA) in 75 mg/kg female mice and SOA squamous cell papillomas in 75 mg/kg male mice were greater than controls. Pyrogallol was carcinogenic in female mice and may have caused tumors in male mice.
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LOAEL
- 5 mg/kg bw/day
- Study duration:
- chronic
- Species:
- rat
- System:
- other: SKIN
Repeated dose toxicity: dermal - local effects
Link to relevant study records
- Endpoint:
- sub-chronic toxicity: dermal
- Type of information:
- experimental study
- Adequacy of study:
- weight of evidence
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- test procedure in accordance with generally accepted scientific standards and described in sufficient detail
- Qualifier:
- no guideline available
- Principles of method if other than guideline:
- - Principle of test:
Based on the subchronic studies, the doses for the 2-year studies in rats and mice were 5, 20 and 75 mg/kg of pyrogallol. The study were conducted in both sexes of F344/N rats mice.
- Short description of test conditions: Groups of 50 male and 50 female rats and mice received dermal applications of pyrogallol in 95% ethanol at doses of 5, 20, or 75 mg/kg, or ethanol vehicle control alone, 5 days per week for up to 104 (rats) or 105 (mice) weeks. Body weights were recorded weekly for 13 weeks and monthly thereafter.
- Parameters analysed / observed: The incidences of microscopic non-neoplastic lesions at the site of application were observed. - GLP compliance:
- yes
- Remarks:
- These studies were conducted in compliance with FDA Good Laboratory Practice for nonclinical laboratory studies (21 CFR 58).
- Limit test:
- no
- Specific details on test material used for the study:
- SOURCE OF TEST MATERIAL
- Source and lot/batch No.of test material: Pyrogallol was obtained from Aceto Corporation (Lake Success, NY; lot number 010326).
- Expiration date of the lot/batch: not specified
- Purity test date: Purity was determined by high-performance liquid chromatography with ultraviolet detection to be greater than 99%.
STABILITY AND STORAGE CONDITIONS OF TEST MATERIAL
- Storage condition of test material: not specified
- Stability under test conditions: not specified
- Solubility and stability of the test substance in the solvent/vehicle: not specified
- Reactivity of the test substance with the solvent/vehicle of the cell culture medium: not specified
TREATMENT OF TEST MATERIAL PRIOR TO TESTING
- Treatment of test material prior to testing: not specified
- Preliminary purification step (if any): not specified
- Final dilution of a dissolved solid, stock liquid or gel: not specified
- Final preparation of a solid: not specified
OTHER SPECIFICS: Dose formulations were prepared by mixing pyrogallol and95% ethanol to give the required concentrations. Dose formulations were analyzed three times during the subchronic study and every three months during the chronic study and were within 10% of target pyrogallol concentrations. - Species:
- rat
- Strain:
- Fischer 344
- Remarks:
- F344/N
- Details on species / strain selection:
- not specified
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: obtained from Taconic Farms, Inc. (Germantown, NY)
- Females (if applicable) nulliparous and non-pregnant: [yes/no] not specified
- Age at study initiation: rats were 6–8 weeks old
- Weight at study initiation: not specified
- Fasting period before study: not specified
- Housing: housed individually
- Diet (e.g. ad libitum): Irradiated NTP-2000 wafer feed (Zeigler Brothers, Inc., Gardners, PA) was available ad libitum.
- Water (e.g. ad libitum): tap water (Columbus, OH, municipal supply) was available ad libitum.
- Acclimation period: quarantined for 11 days
DETAILS OF FOOD AND WATER QUALITY: see above
ENVIRONMENTAL CONDITIONS
- Temperature (°C): not specified
- Humidity (%): not specified
- Air changes (per hr): not specified
- Photoperiod (hrs dark / hrs light): not specified
IN-LIFE DATES: From: To: not specified
Animal care and use were in accordance with the Laboratory Animal Welfare Act of 1966 (P.L. 89–544) as amended and the Public Health Service Policy on Humane Care and Use of Animals. Animals were treated humanely and with regard for alleviation of pain and distress. All animals were housed in facilities accredited by the Association for Assessment and Accreditation of Laboratory Animal Care and all procedures were approved by Battelle's Institutional Animal Care and Use Committee. - Type of coverage:
- other: to naïve skin
- Vehicle:
- ethanol
- Details on exposure:
- TEST SITE
- Area of exposure: Pyrogallol was administered over the application site with a Corning Lambda (Corning, Inc., Corning, NY) single channel pipetter with a disposable polyethylene tip
- % coverage: not specified
- Type of wrap if used:
- Time intervals for shavings or clipplings: An area slightly larger than the interscapular application site was clipped 24 hours before the first dose and weekly thereafter.
REMOVAL OF TEST SUBSTANCE
- Washing (if done): not specified
- Time after start of exposure: not specified
TEST MATERIAL
- Amount(s) applied (volume or weight with unit): Dosing volumes were 0.5 mL/kg body weight
- Concentration (if solution):
- Constant volume or concentration used: yes
- For solids, paste formed: not applicable
VEHICLE
- Justification for use and choice of vehicle (if other than water): not specified
- Amount(s) applied (volume or weight with unit): not specified
- Concentration (if solution): 95%
- Lot/batch no. (if required): not specified
- Purity: not specified
USE OF RESTRAINERS FOR PREVENTING INGESTION: not specified - Analytical verification of doses or concentrations:
- not specified
- Details on analytical verification of doses or concentrations:
- not applicable
- Duration of treatment / exposure:
- two -year study
- Frequency of treatment:
- 5 days per week for 104 weeks
- Dose / conc.:
- 5 mg/kg bw/day
- Remarks:
- pyrogallol in 95% ethanol
- Dose / conc.:
- 20 mg/kg bw/day
- Remarks:
- pyrogallol in 95% ethanol
- Dose / conc.:
- 75 mg/kg bw/day
- Remarks:
- pyrogallol in 95% ethanol
- No. of animals per sex per dose:
- Groups of 50 male and 50 female rats
- Control animals:
- yes, concurrent vehicle
- Positive control:
- no
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: no
- Time schedule: not applicable
- Cage side observations checked in table [No.?] were included. not applicable
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: clinical signs were recorded weekly
DERMAL IRRITATION (if dermal study): no
- Time schedule for examinations: not applicable
BODY WEIGHT: Yes
- Time schedule for examinations: recorded weekly.
FOOD CONSUMPTION: no
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: not applicable
FOOD EFFICIENCY: no
- Body weight gain in kg/food consumption in kg per unit time X 100 calculated as time-weighted averages from the consumption and body weight gain data: not applicable
WATER CONSUMPTION: no
- Time schedule for examinations: not applicable
OPHTHALMOSCOPIC EXAMINATION: no
- Time schedule for examinations: not applicable
- Dose groups that were examined: not applicable
HAEMATOLOGY: no
- Time schedule for collection of blood: not applicable
- Anaesthetic used for blood collection: not applicable
- Animals fasted: not applicable
- How many animals: not applicable
- Parameters checked in table [No.?] were examined. not applicable
CLINICAL CHEMISTRY: no
- Time schedule for collection of blood: not applicable
- Animals fasted: not applicable
- How many animals: not applicable
- Parameters checked in table [No.?] were examined. not applicable
URINALYSIS: no
- Time schedule for collection of urine: not applicable
- Metabolism cages used for collection of urine: not applicable
- Animals fasted: not applicable
- Parameters checked in table [No.?] were examined. not applicable
NEUROBEHAVIOURAL EXAMINATION: No
- Time schedule for examinations: not applicable
- Dose groups that were examined: not applicable
- Battery of functions tested: sensory activity / grip strength / motor activity / other: not applicable
OTHER: Weights of major organs were recorded at necropsy, including heart, liver, kidney, lung, testis, uterus, thymus and thyroid gland.
Animals were observed twice daily and clinical findings were recorded monthly beginning at week 5. - Sacrifice and pathology:
- GROSS PATHOLOGY: Not specified
HISTOPATHOLOGY: Yes - Other examinations:
- no other examinations were performed.
- Statistics:
- To determine statistical differences between incidences, Fisher exact test and poly-3 test were used where applicable. Organ and body weight data were analyzed with the parametric multiple comparison procedures of Dunnett and Williams. Analysis of effects on survival used Cox's [25] method for testing two groups for equality and Tarone's life table test to identify dose-related trends.
- Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- Irritation and/or ulceration of the skin at the site of application were the only chemical-related clinical findings and occurred predominantly in the 20 and 75 mg/kg male and female groups.
- Dermal irritation:
- effects observed, treatment-related
- Description (incidence and severity):
- Lesions at the SOA were morphologically similar to those observed in the 3-month study. The incidences of hyperplasia and hyperkeratosis were significantly greater than those in the vehicle control groups in most dosed groups; incidences of inflammation were significantly increased in several groups treated with 20 or 75 mg/kg. In addition to lesions already seen in the 3-months study, sebaceous gland hyperplasia was significantly increased.
- Mortality:
- mortality observed, treatment-related
- Description (incidence):
- Survival of 75 mg/kg female mice was significantly decreased, as 23 female mice were euthanized before study end due to the presence of ulcers at the SOA.
- Body weight and weight changes:
- no effects observed
- Description (incidence and severity):
- Mean body weights of dosed groups of male and female rats and male mice were similar to that of the vehicle control groups. I
- Food consumption and compound intake (if feeding study):
- not examined
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Description (incidence and severity):
- There were no significant changes in the absolute or relative organ weights at necropsy.
- Gross pathological findings:
- not examined
- Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- Squamous papilloma occurs as an exophytic growth composed of an inner connective tissue core with branching fronds covered by an outer layer of hyperplastic squamous epithelium in male rat exposed to 75 mg/kg Pyrogallol for 2 years.
- Histopathological findings: neoplastic:
- not examined
- Other effects:
- not examined
- Dose descriptor:
- LOAEL
- Effect level:
- 5 mg/kg bw/day
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- body weight and weight gain
- clinical signs
- dermal irritation
- histopathology: non-neoplastic
- mortality
- Dose descriptor:
- NOAEL
- Remarks on result:
- not determinable
- Remarks:
- the adverse toxic effect was observed at the first lowest dose
- Critical effects observed:
- yes
- Lowest effective dose / conc.:
- 5 mg/kg bw/day
- System:
- other: Squamous hyperplasia, Hyperkeratosis, Chronic active inflammation, Ulcer
- Organ:
- skin
- Treatment related:
- yes
- Dose response relationship:
- not specified
- Relevant for humans:
- not specified
- Conclusions:
- Skin at the SOA was the primary site of toxicity for pyrogallol for this 3-months study. In conclusion, dermal administration of pyrogallol caused high incidences of nonneoplastic lesions of the skin at the SOA in male and female rats at doses as low as 5 mg/kg/ day. These studies provide the first comprehensive assessment of pyrogallol toxicity in mammals and can be used to assess possible risks to humans from dermal pyrogallol exposure
- Executive summary:
Pyrogallol (CAS No. 87-66-1), a benzenetriol used historically as a hair dye and currently in a number of industrial applications, was nominated to the National Toxicology Program (NTP) for testing based on lack of toxicity and carcinogenicity data. Three-month and two-year toxicity studies to determine the toxicity and carcinogenicity of pyrogallol when applied to naïve skin (i.e. dermal administration) were conducted in both sexes of F344/N rats and B6C3F1/N mice. In the three-month studies, adult rodents were administered pyrogallol in 95% ethanol 5 days per week for 3 months at doses of up to 150 mg /kg body weight (rats) or 600 mg/kg (mice). Based on the subchronic studies, the doses for the 2-year studies in rats and mice were 5, 20 and 75 mg/kg of pyrogallol. All mice and most rats survived until the end of the three-month study and body weights were comparable to controls. During the 2-year study, survival of dosed rats and male
mice was comparable to controls; however survival of 75 mg/kg female mice was significantly decreased compared to controls. The incidences of microscopic non-neoplastic lesions at the site of application were significantly higher in all dosed groups of rats and mice and in both the 3 months and 2-year studies. In the 2-year study, hyperplasia, hyperkeratosis and inflammation tended to be more severe in mice than in rats, and in the mice they tended to be more severe in females than in males. The incidence of squamous cell carcinoma at the site of application (SOA) in 75 mg/kg female mice and SOA squamous cell papillomas in 75 mg/kg male mice were greater than controls. Pyrogallol was carcinogenic in female mice and may have caused tumors in male mice.
Reference
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- BMDL10
- 31 µg/cm²
- Study duration:
- chronic
- Species:
- rat
Additional information
Justification for classification or non-classification
Based on the available data, the substance does not show a toxicity to a specific target organ (toxicity is local, on skin, at the site of application).
No classification is required.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.